Akt1 Ablation Inhibits, whereas Akt2 Ablation Accelerates, the Development of Mammary Adenocarcinomas in Mouse Mammary Tumor Virus (MMTV)-ErbB2/Neu and MMTV-Polyoma Middle T Transgenic Mice
- 1 January 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (1), 167-177
- https://doi.org/10.1158/0008-5472.can-06-3782
Abstract
Ample evidence to date links the phosphatidylinositol 3-kinase–regulated protein kinase Akt with the induction and progression of human cancer, including breast cancer. However, there are three Akt isoforms with limited information about their specificity during oncogenesis. This study addresses the role of the three isoforms in polyoma middle T (PyMT) and ErbB2/Neu-driven mammary adenocarcinomas in mice. The effects of ablation of Akt1, Akt2, and Akt3 on the induction and the biology of these tumors were dramatically different, with ablation of Akt1 inhibiting, ablation of Akt2 accelerating, and ablation of Akt3 having a small, not statistically significant, inhibitory effect on tumor induction by both transgenes. Whereas PyMT-induced tumors are all invasive, Akt1−/−Neu–induced tumors are more invasive than Akt2−/−Neu–induced tumors. Invasiveness, however, does not always correlate with metastasis. Ablation of individual Akt isoforms does not affect the development of the mammary gland during puberty or the expression of the transgenes. Akt ablation, therefore, influences tumor induction by modulating transgene-induced oncogenic signaling. Immunostaining for Ki-67 and cyclin D1 and terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling assays on tissue sections revealed that the delay of tumor induction in Akt1 knockout mice is due to the inhibitory effects of Akt1 ablation on cell proliferation and survival. Given that these animal models exhibit significant similarities to human breast cancer, the results of the present study may have significant translational implications because they may influence how Akt inhibitors will be used in the treatment of human cancer. [Cancer Res 2007;67(1):167–77]Keywords
All Related Versions
This publication has 34 references indexed in Scilit:
- Dosage-Dependent Effects of Akt1/Protein Kinase Bα (PKBα) and Akt3/PKBγ on Thymus, Skin, and Cardiovascular and Nervous System Development in MiceMolecular and Cellular Biology, 2005
- Akt Blocks Breast Cancer Cell Motility and Invasion through the Transcription Factor NFATMolecular Cell, 2005
- Essential role of protein kinase Bγ (PKBγ/Akt3) in postnatal brain development but not in glucose homeostasisDevelopment, 2005
- Recent advances in the protein kinase B signaling pathwayCurrent Opinion in Cell Biology, 2005
- Activation of Akt-1 (PKB-α) Can Accelerate ErbB-2-Mediated Mammary Tumorigenesis but Suppresses Tumor InvasionCancer Research, 2004
- Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2Genes & Development, 2003
- The Phosphoinositide 3-Kinase PathwayScience, 2002
- Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin EOncogene, 2002
- PKB/AKT: functional insights from genetic modelsNature Reviews Molecular Cell Biology, 2001
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987